Literature DB >> 29978754

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Alankrita Taneja1, Jade Jones2, Stefania Pittaluga3, Irina Maric4, Mohammed Farooqui1, Inhye E Ahn1, Adrian Wiestner1, Clare Sun1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29978754      PMCID： PMC6600815          DOI： 10.1080/10428194.2018.1480775

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature.

Authors:  Bruno Bockorny; Ion Codreanu; Constantin A Dasanu
Journal:  Br J Haematol       Date:  2011-10-24       Impact factor: 6.998

2.  The efficacy of ibrutinib in the treatment of Richter syndrome.

Authors:  Mazie Tsang; Tait D Shanafelt; Timothy G Call; Wei Ding; Asher Chanan-Khan; Jose F Leis; Grzegorz S Nowakowski; Deborah Bowen; Michael Conte; Susan M Schwager; Susan L Slager; Neil E Kay; Curtis A Hanson; Sameer A Parikh
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

3.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

4.  Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Authors:  Mary Ann Anderson; Constantine Tam; Thomas E Lew; Surender Juneja; Manu Juneja; David Westerman; Meaghan Wall; Stephen Lade; Alexandra Gorelik; David C S Huang; John F Seymour; Andrew W Roberts
Journal:  Blood       Date:  2017-05-04       Impact factor: 22.113

5.  Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?

Authors:  Sotirios Sachanas; Gerassimos A Pangalis; Maria Moschogiannis; Xanthi Yiakoumis; Efstathios Koulieris; Pantelis Tsirkinidis; Christina Kalpadakis; Dimitra Rontogianni
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

6.  Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.

Authors:  Siobhan Glavey; John Quinn; Mary McCloy; Jeremy Sargent; Yvonne McCartney; Mark Catherwood; Teresa Marafioti; Mary Leader; Philip Murphy; Patrick Thornton
Journal:  Eur J Haematol       Date:  2017-07-05       Impact factor: 2.997

7.  Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus.

Authors:  H Momose; E S Jaffe; S S Shin; Y Y Chen; L M Weiss
Journal:  Am J Surg Pathol       Date:  1992-09       Impact factor: 6.394

8.  Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.

Authors:  Idanna Innocenti; Davide Rossi; Giulio Trapè; Francesco Autore; Luigi Maria Larocca; Vincenzo Gomes; Michaela Cerri; Paolo Falcucci; Simona Sica; Gianluca Gaidano; Luca Laurenti
Journal:  Hematol Oncol       Date:  2018-02-27       Impact factor: 5.271

9.  Ibrutinib has some activity in Richter's syndrome.

Authors:  S Giri; A Hahn; G Yaghmour; M G Martin
Journal:  Blood Cancer J       Date:  2015-01-30       Impact factor: 11.037

10.  Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Authors:  Anthony R Mato; Chadhi Nabhan; Meghan C Thompson; Nicole Lamanna; Danielle M Brander; Brian Hill; Christina Howlett; Alan Skarbnik; Bruce D Cheson; Clive Zent; Jeffrey Pu; Pavel Kiselev; Andre Goy; David Claxton; Krista Isaac; Kaitlin H Kennard; Colleen Timlin; Daniel Landsburg; Allison Winter; Sunita D Nasta; Spencer H Bachow; Stephen J Schuster; Colleen Dorsey; Jakub Svoboda; Paul Barr; Chaitra S Ujjani
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941
View more
  1 in total

1.  Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.

Authors:  Clare Sun; Pia Nierman; Ellen K Kendall; Jean Cheung; Michael Gulrajani; Sarah E M Herman; Christopher Pleyer; Inhye E Ahn; Maryalice Stetler-Stevenson; Constance M Yuan; Irina Maric; Erika M Gaglione; Hailey M Harris; Stefania Pittaluga; Min Hui Wang; Priti Patel; Mohammed Z H Farooqui; Raquel Izumi; Ahmed Hamdy; Todd Covey; Adrian Wiestner
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.